Stem Cells In-Depth Focus 2016
Posted: 16 June 2016 | Andreas Reimer (CEO: Tangea), Anton Simeonov, David Bailey (IOTA Pharmaceuticals), Ilyas Singeç (National Center for Advancing Translational Sciences), Sheraz Gul (Fraunhofer-IME SP) | No comments yet
Featured in this Stem Cells In-depth Focus: Translating stem cell biology into drug discovery; Mechanism-informed phenotypic screening – the missing link for cancer drug discovery; Analysis of human stem cell interactions at the single-cell resolution…
This Stem Cells In-Depth Focus is restricted - login or subscribe free to access
Thank you for visiting our website. To access this content in full you'll need to login. It's completely free to subscribe, and in less than a minute you can continue reading. If you've already subscribed, great - just login.
Why subscribe? Join our growing community of thousands of industry professionals and gain access to:
- quarterly issues in print and/or digital format
- case studies, whitepapers, webinars and industry-leading content
- breaking news and features
- our extensive online archive of thousands of articles and years of past issues
- ...And it's all free!
Click here to Subscribe today Login here
Related topics
Stem Cells
Related organisations
Fraunhofer-IME SP, IOTA Pharmaceuticals, National Center for Advancing Translational Sciences, Takara Bio, Tangea
Related people
Andreas Reimer, Anton Simeonov, David Bailey, Ilyas Singeç, Sheraz Gul